The gut microbiota synthesize hundreds of molecules, many of which are known to impact 24 host physiology. Among the most abundant metabolites are the secondary bile acids deoxycholic 25 acid (DCA) and lithocholic acid (LCA), which accumulate at ~500 µM and are known to block C. 26 difficile growth 1 , promote hepatocellular carcinoma 2 , and modulate host metabolism via the GPCR 27 TGR5 3 . More broadly, DCA, LCA and their derivatives are a major component of the recirculating 28 bile acid pool 4 ; the size and composition of this pool are a target of therapies for primary biliary 29 cholangitis and nonalcoholic steatohepatitis. Despite the clear impact of DCA and LCA on host 30 physiology, incomplete knowledge of their biosynthetic genes and a lack of genetic tools in their 31 native producer limit our ability to modulate secondary bile acid levels in the host. Here, we 32 complete the pathway to DCA/LCA by assigning and characterizing enzymes for each of the steps 33 in its reductive arm, revealing a strategy in which the A-B rings of the steroid core are transiently 34 converted into an electron acceptor for two reductive steps carried out by Fe-S flavoenzymes. 35
MAIN TEXT 43
The human gut microbiota harbor hundreds of pathways, most of which are encoded by genes that 44
have not yet been identified [5] [6] [7] [8] . Their small molecule products are of interest for three reasons: (i) Most 45 derive predominantly or exclusively from the microbiota (i.e., there is no host source), and many enter the 46 circulation, where they can have effects on peripheral tissues and organ systems. (ii) Their concentrations 47 are similar to or exceed that of a typical drug; for example, indoxyl sulfate can accumulate in the human 48 host at 130 mg/day 9 . Moreover, their concentration ranges are large, typically >10-fold 10 , which could help 49 explain microbiome-mediated biological differences among people. (iii) Of the few high-abundance 50 molecules whose biological functions are well understood, most are ligands for a key host receptor; for 51 example, short-chain fatty acids modulate host immune function via GPR41/GPR43 [11] [12] [13] . Thus, high-52
abundance, microbiota-derived molecules are responsible for a remarkably broad range of phenotypes 53 conferred on the host by bacteria. 54
Among these pathways, 7a-dehydroxylation of the primary bile acids cholic acid (CA) and 55 chenodeoxycholic acid (CDCA) is particularly notable because the organisms that carry it out are present 56 at very low abundance-an estimated 1:10 6 in a typical gut community 14 -yet they fully process a pool of 57 primary bile acids that is ~1 mM in concentration 15 . Therefore, the flux through this pathway must be very 58 high in the small subset of cells in which it operates, and the low-abundance organisms in the microbiome 59 that perform this transformation have an unusually large impact on the pool of metabolites that enters the 60 host. This pathway's products-deoxycholic acid (DCA) and lithocholic acid (LCA)-are the most abundant 61 secondary bile acids in humans (up to 450-700 µM in cecal contents) 16 , and are known to be important in 62 three biological contexts: prevention of Clostridium difficile outgrowth 1 , induction of hepatocellular 63 carcinogenesis 2 , and modulation of the host metabolic and immune responses [17] [18] [19] . More broadly, DCA, 64 LCA, and their derivatives are a major component of the recirculating bile acid pool, representing >90% of 65 the pool in the intestine and >25% in the gallbladder 15 . These microbiome-derived bile acids are therefore 66 central to understanding the efficacy of therapeutics that target the bile acid pool and are approved or in 67 clinical trials for primary biliary cholangitis and nonalcoholic steatohepatitis 4 . 68
In pioneering work, Hylemon and coworkers showed that the gut bacterium Clostridium scindens 69 VPI 12708 carries out the 7a-dehydroxylation of CA to produce DCA 20 . CA serves as an inducer of 7a-70 dehydroxylation, leading to the discovery of a bile-acid-induced operon (termed bai) containing eight genes 71 ( Fig. 1) 21 . The postulated pathway consists of an oxidative arm in which four electrons are removed from 72 the 3,7-dihydroxy moiety in the A/B ring system to generate a 3-oxo-4,5-6,7-didehydro intermediate, 73
followed by a reductive arm in which six electrons are deposited to yield the 7-dehydroxylated product 21 74 (Extended Data Fig. 1 ). Through heterologous expression and characterization of individual bai gene 75 products, enzymes have been attributed to each step of the oxidative arm of the pathway 22-27 , but the 76 reductive arm of the pathway remains poorly characterized. Given that this pathway generates abundant 77 metabolites with broad biological impact, it is notable that the set of enzymes necessary and sufficient for 78 7a-dehydroxylation have not yet been defined. A complete understanding of the pathway would enable 79 efforts to control the composition of the bile acid pool by engineering the microbiome. 80
Here, by purifying and assaying pathway enzymes under anaerobic conditions, we reconstituted 81 7a-dehydroxylation in vitro, demonstrating that a core set of six enzymes are necessary and sufficient for 82 the conversion of CA to DCA and revealing an unusual redox strategy in which the steroid core is 83 transiently converted into an electron acceptor. We then transferred the pathway from its genetically 84 intractable producer Clostridium scindens into Clostridium sporogenes, conferring production of DCA and 85 LCA on a non-producing commensal bacterial species. These data establish a complete pathway for two 86 central components of the bile acid pool, and they provide a genetic basis for controlling the bile acid output 87 of the microbiome. 88 89
Biochemical reconstitution of bile acid 7a-dehydroxylation 90
We first set out to de-orphan the remaining steps in the 7a-dehydroxylation pathway. Since 91 previous studies of the bai enzymes involved expressing them individually in E. coli, we reasoned that an 92 alternative approach in which enzymes were purified, mixed, and assayed in vitro could help delineate the 93 set of enzymes necessary and sufficient for 7a-dehydroxylation. Given that the eight-gene bai operon is 94 shared among all known 7a-dehydroxylating strains, we focused our efforts on the enzymes encoded by 95 the operon. We cloned three orthologs of each enzyme, expressed them individually in E. coli under micro-96 aerobic conditions, and purified them anaerobically as N-terminal His6 fusions. Using this strategy, we 97 obtained at least one soluble, purified ortholog of each Bai enzyme (Extended Data Fig. 2 ). When we 98 incubated a mixture of the purified Bai enzymes with CA, NAD + , coenzyme A, and ATP under anaerobic 99 conditions and monitored the reaction by LC-MS, we observed the time-dependent conversion of CA to 100 DCA, indicating that the combination of BaiB, BaiCD, BaiA2, BaiE, BaiF, and BaiH is sufficient for 7a-101 dehydroxylation; no additional enzymes are required ( Fig. 2a, b) . 102
To test our hypotheses regarding the order of steps in the pathway, we performed stepwise 103 reconstitutions in which enzymes were added one at a time and intermediates were allowed to build up at 104 each step in the pathway (Fig. 2c) . From these data, we draw two conclusions: First, the six enzymes used 105 in the reconstitution are not just sufficient but also necessary, and the pathway proceeds according to the 106 scheme shown in Fig. 4 . We directly observed mass ions consistent with each of the proposed 107 intermediates, providing direct evidence for the previously proposed portion of the biosynthetic route. In 108 spite of its conservation in all known dehydroxylating species, BaiI is dispensable for CA dehydroxylation 109 in vitro. Since BaiI is a predicted D 5 -ketosteroid isomerase, it may process a substrate other than CA, likely 110 one with a 4,5-or 5,6-olefin. 111 Second, to our surprise, the absence of BaiH caused the pathway to stall at the highly oxidized 112 intermediate 3-oxo-4,5-6,7-didehydro-DCA, and its addition resulted in two successive 2e-reductions to 113 form 3-oxo-DCA. BaiH had previously been proposed to oxidize an alternative substrate, 3-oxo-4,5-114 dehydro-UDCA 25 , so a potential role in the reductive arm of the pathway was unexpected. To explore this 115 finding further, we incubated purified BaiH with synthetic 3-oxo-4,5-6,7-didehydro-DCA; we observed that 116 the enzyme catalyzes a 2e-reduction to 3-oxo-4,5-dehydro-DCA, but does not reduce this intermediate 117 further (Fig. 3e) . Notably, 3-oxo-4,5-dehydro-DCA does not build up in the reconstitution reaction 118 containing BaiH, suggesting that another enzyme present in the mixture catalyzes the second reductive 119 step. Hypothesizing that the BaiH homolog BaiCD catalyzes the second reductive step, we incubated it 120 with synthetic 3-oxo-4,5-dehydro-DCA, revealing that it reduces this substrate to 3-oxo-DCA (Extended 121 Data Fig. 3 ). Together, these data show that the pathway employs an unusual redox strategy in which the 122 A and B rings of the steroid core are converted into a highly oxidized intermediate, 3-oxo-4,5-6,7-123 didehydro-DCA; and that the two key reductive steps are catalyzed by two homologous enzymes in the 124 Fe-S flavoenzyme superfamily, BaiH and BaiCD. 125
Finally, the last step in the pathway-reduction of 3-oxo-DCA to DCA-is carried out by BaiA2, as 126 confirmed by assaying purified BaiA2 alone (Extended Data Fig. 4) . Thus, BaiA2 and BaiCD both act 127 twice in the pathway, catalyzing its first two and last two redox steps. 128 129
Engineering the 7a-dehydroxylation pathway into C. sporogenes 130
Having determined the set of enzymes that are necessary and sufficient for the pathway, we sought 131 to gain genetic control over the pathway as a first step toward engineering the bile acid output of the gut 132 community. We began by attempting to construct a mutation in the baiCD gene of the native producer, C. 133 scindens, using the ClosTron group II intron system; however, we were unsuccessful due to an inability to 134 introduce DNA constructs into C. scindens by conjugation. As an alternative approach, we considered 135 expressing the bai pathway in a gut commensal that is unable to carry out 7a-dehydroxylation; however, 136 methods for transferring pathways in Clostridium are underdeveloped. The pathways for isobutanol (five 137 genes) and 1,3-propanediol (three genes) have been transferred into C. cellulolyticum and C. 138 acetobutylicum 28,29 , and a functional mini-cellulosome operon was introduced into the genome of C. 139 acetobutylicum 30 . But to our knowledge, no more than a few genes have been transferred into Clostridium, 140 and no pathway from the human microbiome has been mobilized from one Clostridium species to another. 141
We selected Clostridium sporogenes ATCC 15579 as the recipient for two reasons: it is related to 142 C. scindens, making it likely that ancillary metabolic requirements for the pathway (e.g., cofactor 143 biogenesis) would be met; and genetic tools have been developed that enable plasmids to be transformed 144 into C. sporogenes 31 . Our initial attempts to clone the entire 8-gene bai operon (baiB-baiI) into an E. coli-145 C. sporogenes shuttle vector failed to yield clones harboring the complete operon. Reasoning that there 146 might be a gene in the cluster that is toxic to E. coli, we cloned various fragments of the cluster under the 147 control of different promoters (detailed in Supplementary Table 1) , eventually managing to split the cluster 148 into three pieces, each in its own E. coli-C. sporogenes shuttle vector: baiB-baiF in pMTL83153 (pMF01), 149 baiG in pMTL83353 (pMF02), and baiH-baiI in pMTL83253 (pMF03) ( Fig. 3a, Extended Data Fig. 5 ). 150
Genes in pMF01 and pMF03 were placed under the control of the spoIIE promoter from C. sporogenes 151 ATCC 15579, which is expressed during the late stages of Clostridium growth 32 , while baiG in pMF02 was 152 driven by the strong fdx promoter. We conjugated these plasmids sequentially into C. sporogenes to yield 153 strain MF001. 154
When incubated with CA, MF001 produces DCA in a time-dependent manner, in contrast to a 155 control strain that harbors only the transporter (baiG) (Fig. 3b, c) , which does not. Additionally, MF001 156 converts CDCA to LCA (Extended Data Fig. 6 ). These data show that the eight genes in the core bai 157 cluster ( Fig. 1 ) are sufficient to confer bile acid 7a-dehydroxylation on C. sporogenes, although they do 158 not rule out the participation of one or more genes endogenous to C. sporogenes. 159
160

Identifying branch points in the 7a-dehydroxylation pathway 161
To uncover potential branch points for engineering the biosynthesis of non-native pathway 162 products, we constructed a set of strains in which each of the eight genes were individually deleted 163 (Extended Data Fig. 5 ). We grew these strains with CA and assayed their culture supernatant for the 164 build-up of intermediates ( Fig. 3d) . Deletion of genes encoding enzymes in the oxidative arm of the 165 pathway resulted in the buildup of early pathway intermediates, as expected. Two exceptions were the 166 baiE mutant, which produced only cholyl-CoA, potentially due to a polar effect on the transcription of 167 downstream genes; and the baiF-deficient strain, which generated a small quantity of the final product 168
DCA, suggesting there might be a compensatory CoA hydrolase (of note, C. sporogenes harbors two baiF 169 homologs, CLOSPO_02756 and CLOSPO_00308), or that non-enzymatic hydrolysis of the CoA thioester 170 happens to some extent in vivo. 171 Intriguingly, the baiH mutant accumulates a key intermediate in the reductive arm of the pathway, 172 3-oxo-4,5-6,7-didehydro-DCA ( Fig. 3d) , supporting our finding that BaiH catalyzes the first reductive step 173 in the pathway and providing genetic access to a key intermediate in the pathway. Moreover, strains of C. 174 sporogenes expressing BaiG/BaiH and BaiG/BaiCD convert, respectively, 3-oxo-4,5-6,7-didehydro-DCA 175 to 3-oxo-4,5-dehydro-DCA and 3-oxo-4,5-dehydro-DCA to 3-oxo-DCA ( Fig. 3e) , providing access to 176 intermediates that do not accumulate in a culture of C. scindens. Notably, the fully oxidized and partially 177 reduced intermediates are branch points for the production of alternative bile acid metabolites including 178 allo (5a) bile acids, which have important biological activities including the induction of regulatory T cells 33 . 179
Thus, gaining genetic control over the pathway by expressing it in an alternative gut provides opportunities 180 for rational and deliberate control of bile acid metabolism and the production of alternative molecules with 181 distinct biological properties. 182 183 7a-dehydroxylation as a model for other microbiome-derived pathways 184
These results establish the complete 7a-dehydroxylation pathway, bringing this pathway closer to 185 the level of knowledge we have about endogenous human metabolic pathways. Our work underscores 186 that little is known about the biochemistry of metabolic pathways in the microbiome, in spite of the fact that 187 they operate inside the human organism and produce abundant molecules that modulate host biology. The gut microbiome harbors hundreds of pathways, many of which likely modulate host biology, 208 but to date these pathways have not been a target of engineering. This stands in contrast to natural product 209 pathways from terrestrial and marine microorganisms and plants, which are commonly expressed in 210 heterologous hosts 37,38 and engineered to generate non-native products 39 . Two technology gaps need to 211 be overcome in order to make microbiome-derived pathways amenable to engineering: (i) efficient 212 strategies for identifying pathways for known metabolites and small molecule products of orphan gene 213 clusters, and (ii) tools for transferring pathways into bacterial hosts native to the gut and manipulating them 214 to produce novel molecules. The work described here is a starting point for these efforts, and provides set 215 of tools for deorphaning, heterologously expressing, and engineering pathways from Clostridium as a new 216 way of controlling the chemical output of the microbiome. 217
218
METHODS 219
Bacterial strains, culture conditions, and bile acids 220
Clostridium scindens VPI 12708 and Clostridium sporogenes ATCC 15579 were obtained from the 221 Japan Collection of Microorganisms (JCM) and the American Type Culture Collection (ATCC), 222
respectively. Engineered C. sporogenes strains used in this study are shown in Supplementary Table 2 . 223 They were cultured in TYG (3% w/v tryptone, 2% w/v yeast extract, 0.1% w/v sodium thioglycolate) broth 224 at 37 ˚C in an anaerobic chamber from Coy Laboratories. Escherichia coli CA434 (HB101/pRK24) was 225 cultured at 37 ˚C in LB broth supplemented with 12 µg/mL tetracycline and 100 µg/mL carbenicillin. In 226 addition, 20 µg/mL chloramphenicol, 100 µg/mL spectinomycin or 250 µg/mL erythromycin was used for 227 the selection of series of plasmids of pMTL83153, pMTL83353 or pMTL83253 respectively. Plasmids used 228 in this study are shown in Supplementary Table 1 . Cholic acid (1), chenodeoxycholic acid, deoxycholic 229 acid (9) and lithocholic acid were purchased from Sigma-Aldrich. 3-oxo-cholic acid (3b) and 3-oxo-230 deoxycholic acid (8) were purchased from Steraloids. 3-oxo-4,5-6,7-didehydro-DCA (6) and 3-oxo-4,5-231 dehydro-DCA (7) were synthesized using previously reported procedures 40 . Structural assignments for the 232 remaining pathway intermediates and derivatives shown in Fig. 2 and Fig. 3 are provisional, and were 233 made on the basis of mass spectra, retention times, and comparison to chemically related standards. 234 235
Cloning of the bai operon 236
All PCR amplification was conducted using PrimeSTAR Max DNA polymerase (Takara Bio) 237 according to the manufacturer's instructions. Sequences of primers for target genes and cloning vectors 238 were shown in Supplementary Table 3 . For the heterologous expression of bai genes under fdx promoter, 239 pMTL vectors were amplified with primers 1 and 2. For the expression of bai genes under spoIIE promoter, 240 pMTL vectors harboring spoIIE promoter was constructed at first. pMTL vectors were amplified with 241 primers 1 and 3 to remove the fdx promoter and spoIIE promoter region, which is the 277 bp sequence 242 upstream of CLOSPO_01065, was amplified with primers 4 and 5. Then these two PCR fragments were 243 assembled by overlap PCR. The target gene sequences were amplified with the primers pair shown in 244 Supplementary Table 3 . PCR fragments were assembled with the amplified fragments of vectors using were pipetted on TYG agar plate without antibiotics and the plate was incubated anaerobically at 37 ˚C for 257 2 days. The bacterial biomass was scraped up and resuspended in 300 µL of PBS. The whole cell 258 suspension was then plated on TYG agar plates supplemented with 250 µg/mL D-cycloserine and 259 appropriate antibiotics (15 µg/mL thiamphenicol for pMTL83153, 500 µg/mL spectinomycin for pMTL83353 260 or 5 µg/mL erythromycin for pMTL83253). After a few days, antibiotic resistant colonies were picked and 261 re-streaked on agar containing the same antibiotic. The resulting clones were confirmed by PCR 262 amplification using appropriate primers ( Supplementary Table 3 ). Multiple plasmids were introduced 263 sequentially, using the same procedure. 
Cloning of bai operon genes 283
To increase the probability of assembling a complete bai operon, we cloned the genes encoding 284 baiB, baiA2, baiCD, baiE, baiF, and baiH from Clostridium scindens VPI12708, Clostridium hylemonae, 285
and Clostridium hiranonis using the primers in Supplementary Table 4 and FeCl3) housed in a 2 L PYREX® media bottle. Cultures were grown with constant aeration using a sparging 308 stone attached to a pressurized, 0.22 μm filtered air source all in a water bath maintained at 37 °C. After 309 5 hr, aeration was stopped and the culture was placed in an ice bath for 1 hr. The culture was returned to 310 a 22 °C water bath and light aeration was resumed. After 5 min, cysteine was added to a final concentration 311 of 600 μM. The culture was grown at 22 °C for ~ 20 hr before being harvested by centrifugation at 10,000 312
x g. Cell pellets were flash frozen and stored in liquid N2 until purification. All subsequent steps were 313 carried out in an MBraun anaerobic chamber maintained at < 0.1 ppm oxygen (MBraun, Stratham, NH). 314
Plastics were brought into the chamber and allowed to sit for two weeks before use. All solvents and buffer 315 stocks were degassed by sparging with argon gas for 4 hr before being taken into the chamber. In a typical 316 purification, ~30 grams of BaiCD or BaiH cell paste was resuspended in 30 mL of lysis buffer containing 317 50 mM HEPES, pH 7.5, 300 mM KCl, 4 mM imidazole, 10 mM 2-mercaptoethanol (BME), 10% glycerol, 1 318 mM FMN, 1 mM FAD, and 1% Triton-X305. The resuspension was subjected to 50 rounds of sonic 319 disruption (80% output, 3 s pulse on, 12 s pulse of) at 4 °C. The lysate was cleared by centrifugation at 4 320 °C for 1 hr at 15,000 × g. The supernatant was loaded with an ÄKTA express FPLC system onto a 5 mL 321 fast-flow HisTrap TM column (GE Healthcare Life Sciences) equilibrated in lysis buffer lacking FMA, FAD, 322
and Triton-X305. The column was washed with 10 column volumes of lysis buffer before elution with 5 mL 323 of buffer containing 50 mM HEPES, pH 7.5, 300 mM KCl, 300 mM imidazole, 10 mM BME, and 10% 324 glycerol. The fractions containing protein, based on absorbance at 280 nm, were pooled and reconstituted 325 with Fe and sulfur as previously described. The reconstituted proteins were then passed over a HiPrep using a sparging stone attached to a pressurized, 0.22 μm filtered air source in a water bath at 37 °C. 338
After 5 hr, aeration was stopped and the culture was placed in an ice bath for 1 hr. The culture was 339 returned to a 22 °C water bath and light aeration was resumed. The culture was grown at 22 °C for ~ 20 340 hr before being harvested by centrifugation at 10,000 x g. Cell pellets were flash frozen and stored in liquid 341 N2 until purification. All subsequent steps were carried out in an MBraun anaerobic chamber maintained 342 at < 0.1 ppm oxygen as above with minor modifications. Briefly, a typical purification, ~ 30 -40 grams of 343 cell paste was resuspended in 30 -40 mL of lysis buffer containing 50 mM HEPES, pH 7.5, 300 mM KCl, 344 4 mM imidazole, 10 mM 2-mercaptoethanol (BME), 10% glycerol, and 1% Triton-X305. The resuspension 345 was subjected to 50 rounds of sonic disruption (80% output, 3 s pulse on, 12 s pulse of) at 4 °C. The lysate 346 was cleared by centrifugation at 4 °C for 1 hr at 15,000 × g. The supernatant was loaded with an ÄKTA 347 
